Munhoz Alexandre Mendonça, Aldrighi Claudia, Montag Eduardo, Arruda Eduardo Gustavo, Aldrighi José Mendes, Filassi José Roberto, Ferreira Marcus Castro
São Paulo, Brazil From the Division of Plastic Surgery; University of São Paulo School of Medicine.
Plast Reconstr Surg. 2007 May;119(6):1637-1649. doi: 10.1097/01.prs.0000246406.68739.e4.
Although use of the latissimus dorsi myocutaneous flap associated with the Biodimensional anatomical expander implant system (McGhan 150) is a reliable technique, little information has been available regarding clinical outcome following periareolar skin-sparing mastectomy reconstruction. The purpose of this study was to analyze the feasibility of the technique, surgical planning, and its outcome following skin-sparing mastectomy.
Thirty-two patients underwent immediate unilateral latissimus dorsi myocutaneous flap/Biodimensional anatomical expander implant system breast reconstruction. Mean follow-up was 18 months. The technique was indicated in patients with small- or moderate-volume breasts with or without ptosis, in whom the use of abdominal flaps was precluded. Flap and donor-site complications were evaluated. Information on anesthetic results and patient satisfaction was collected.
Seventy-two percent had tumors measuring 2 cm or less (T1) and 78 percent were stage 0 and I according to American Joint Committee on Cancer criteria. Breast skin complications occurred in 9.4 percent. Two patients presented small breast skin necrosis, and in one patient, a wound dehiscence was observed. Donor-site complications, all represented by seroma, occurred in 12.5 percent. The cosmetic result was considered good or very good in 84.4 percent, and the majority of patients were either very satisfied or satisfied. No local recurrences were observed. All complications except two were treated by conservative means.
The latissimus dorsi myocutaneous flap/Biodimensional anatomical expander implant system is a simple and reliable technique for periareolar skin-sparing mastectomy reconstruction. Success depends on patient selection, coordinated planning with the oncologic surgeon, and careful intraoperative and postoperative management.
尽管使用背阔肌肌皮瓣联合生物三维解剖扩张器植入系统(麦加恩150型)是一种可靠的技术,但关于乳晕周围皮肤保留乳房切除术后重建的临床结果,目前可用信息较少。本研究的目的是分析该技术在皮肤保留乳房切除术后的可行性、手术规划及其结果。
32例患者接受了即刻单侧背阔肌肌皮瓣/生物三维解剖扩张器植入系统乳房重建。平均随访时间为18个月。该技术适用于乳房体积小或中等、有或无乳房下垂且不能使用腹部皮瓣的患者。评估皮瓣和供区并发症。收集麻醉效果和患者满意度信息。
72%的患者肿瘤大小为2厘米或更小(T1期),根据美国癌症联合委员会标准,78%为0期和I期。乳房皮肤并发症发生率为9.4%。2例患者出现小面积乳房皮肤坏死,1例患者观察到伤口裂开。供区并发症均为血清肿,发生率为12.5%。84.4%的患者美容效果被评为良好或非常好,大多数患者非常满意或满意。未观察到局部复发。除2例并发症外,所有并发症均采用保守治疗。
背阔肌肌皮瓣/生物三维解剖扩张器植入系统是乳晕周围皮肤保留乳房切除术后重建的一种简单可靠的技术。成功取决于患者的选择、与肿瘤外科医生的协同规划以及仔细的术中及术后管理。